Fremanezumab News
Fremanezumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Fremanezumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
- Evidence level: L5
- Predicted indications (20):
- migraine with brainstem aura (99.9%)
- migraine disorder (99.9%)
- migraine with or without aura, susceptibility to (99.3%)
- atrophoderma vermiculata (99.0%)
- ulerythema ophryogenesis (98.6%)
- heparin cofactor 2 deficiency (96.9%)
- antithrombin deficiency type 2 (96.4%)
- factor 5 excess with spontaneous thrombosis (96.2%)
- thrombophilia (94.3%)
- amenorrhea (disease) (92.7%)
- sciatic neuropathy (90.3%)
- hemorrhagic disease of newborn (80.8%)
- severe nonproliferative diabetic retinopathy (66.0%)
- hyperemesis gravidarum (disease) (64.2%)
- hyperparathyroidism, primary, caused by water clear cell hyperplasia (60.2%)
- omphalocele (disease) (59.8%)
- sudden arrhythmia death syndrome (59.3%)
- cauda equina syndrome (59.0%)
- prekallikrein deficiency (58.9%)
- Coronavinae infectious disease (58.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.